文献速递肝病

白细胞介素-19通过SUMO化C/EBPβ限制促炎巨噬细胞浸润改善药物性肝损伤

Interleukin-19 ameliorates drug-induced liver injury by limiting proinflammatory macrophage infiltration via SUMOylation of C/EBPβ.
PubMed 文献 · J Hepatol · 2026-06-18

该研究利用Il19基因敲除小鼠和髓系细胞特异性Il20r2敲除小鼠建立对乙酰氨基酚诱导的肝损伤模型,并结合单细胞RNA测序分析肝脏巨噬细胞亚群。结果显示IL-19通过促进C/EBPβ的SUMO化下调其表达,减少S100A8/A9+促炎巨噬细胞浸润,从而减轻早期药物性肝损伤,提示IL-19是潜在治疗靶点。

要点

  • IL-19缺失加重对乙酰氨基酚诱导的肝损伤,伴促炎巨噬细胞浸润增加。
  • 重组IL-19治疗可抑制促炎巨噬细胞浸润并减轻肝损伤。
  • IL-19通过促进C/EBPβ SUMO化抑制S100A8/A9等促炎基因转录。

核心结论

  • IL-19通过限制促炎巨噬细胞浸润改善早期对乙酰氨基酚诱导的肝损伤,是潜在治疗靶点。

研究设计与样本

  • 研究使用Il19缺陷小鼠和髓系细胞特异性Il20r2敲除小鼠建立对乙酰氨基酚诱导的肝损伤模型。
  • 采用单细胞RNA测序分析肝脏巨噬细胞亚群。

主要发现

  • Il19缺陷小鼠对对乙酰氨基酚诱导的肝损伤易感性增加,伴促炎巨噬细胞浸润显著增加。
  • 重组IL-19治疗显著抑制促炎巨噬细胞浸润并减轻对乙酰氨基酚诱导的肝损伤。
  • 髓系细胞特异性Il20r2缺陷加重肝损伤,与S100A8/A9+促炎巨噬细胞浸润增加相关。
  • IL-19通过促进C/EBPβ的翻译后SUMO化下调其表达,减少C/EBPβ介导的促炎基因转录(包括调控S100A8/A9表达的基因)。

临床怎么用

  • IL-19可能作为对乙酰氨基酚诱导的急性肝损伤的潜在治疗靶点,但尚需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Acetaminophen (APAP) overdose is the leading cause of acute liver failure in Western countries. However, the inflammatory mechanisms underlying APAP-induced liver injury (AILI) remain poorly understood. Interleukin (IL)-19 exerts its biological effects through binding to the IL-20 receptor complex (IL-20R1/IL-20R2). This study aimed to investigate the role of IL-19 in AILI. METHODS: Il19-deficient mice and myeloid cell-specific Il20r2 knockout mice were generated and subjected to AILI. Single-cell RNA sequencing (ScRNA-seq) was performed to analyze hepatic macrophage subsets. RESULTS: Il19-deficient mice exhibited increased susceptibility to AILI, accompanied by a distinct transcriptional profile and a marked increase in proinflammatory macrophage infiltration. Treatment with recombinant IL-19 significantly suppressed proinflammatory macrophage infiltration and attenuated AILI. scRNA-seq analysis revealed that myeloid cell-specific Il20r2 deficiency exacerbated AILI and was associated with increased infiltration of S100A8/A9+ proinflammatory macrophages. Mechanistically, IL-19 downregulated CCAAT/enhancer-binding protein β (C/EBPβ) expression in macrophages by promoting its post-translational SUMOylation. This reduced C/EBPβ-mediated transcription of proinflammatory genes, including those regulating S100A8/A9 expression, thereby ameliorating AILI. CONCLUSIONS: IL-19 plays a key role in limiting proinflammatory macrophage infiltration and thereby ameliorates early-stage AILI. These findings suggest that IL-19 may represent a promising therapeutic target for AILI. IMPACT AND IMPLICATIONS: Although IL-19 signals through the IL-20 receptor complex (IL-20R1/IL-20R2), its role in liver disease remains incompletely understood. Here, we show that IL-19 protects against APAP-induced liver injury by restricting the infiltration of S100A8/A9+ proinflammatory macrophages. Both Il19-deficient mice and myeloid cell-specific Il20r2-deficient mice displayed increased susceptibility to APAP hepatotoxicity and enhanced accumulation of S100A8/A9+ proinflammatory macrophages. Mechanistically, IL-19 promotes C/EBPβ SUMOylation, thereby suppressing proinflammatory gene expression. These findings identify IL-19 as a potential therapeutic target for acute liver injury.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Xiao P, Zai Q, Ma N, et al. Interleukin-19 ameliorates drug-induced liver injury by limiting proinflammatory macrophage infiltration via SUMOylation of C/EBPβ. J Hepatol. 2026. PMID: 42314952. doi:10.1016/j.jhep.2026.05.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。